Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, and PI3K/AKT/mTOR signaling in cancer.
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Novel insights into the study of goblet cell hypersecretion in allergic rhinitis
Inhibition of TRPV1 attenuates innate nasal epithelial responses via NF-κB signaling pathway in allergic rhinitis
Dihydroorotate dehydrogenase inhibition activates STING pathway and pyroptosis to enhance NK cell-dependent tumor immunotherapy
Regulation of the immune microenvironment by SUMO in diabetes mellitus
Research progress on NUSAP1 and its role in digestive system neoplasms
A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.
636 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
Outcome analysis of Phase I trial patients with metastatic<i>KRAS</i>and/or<i>TP53</i>mutant non-small cell lung cancer
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation
<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy